CN104311643B - 基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原及其应用 - Google Patents
基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原及其应用 Download PDFInfo
- Publication number
- CN104311643B CN104311643B CN201410535171.4A CN201410535171A CN104311643B CN 104311643 B CN104311643 B CN 104311643B CN 201410535171 A CN201410535171 A CN 201410535171A CN 104311643 B CN104311643 B CN 104311643B
- Authority
- CN
- China
- Prior art keywords
- don
- antigen
- deoxynivalenol
- analogue
- phage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 71
- 108091007433 antigens Proteins 0.000 title claims abstract description 71
- 102000036639 antigens Human genes 0.000 title claims abstract description 71
- LINOMUASTDIRTM-QGRHZQQGSA-N deoxynivalenol Chemical compound C([C@@]12[C@@]3(C[C@@H](O)[C@H]1O[C@@H]1C=C(C([C@@H](O)[C@@]13CO)=O)C)C)O2 LINOMUASTDIRTM-QGRHZQQGSA-N 0.000 title abstract description 9
- 229930002954 deoxynivalenol Natural products 0.000 title abstract description 9
- LINOMUASTDIRTM-UHFFFAOYSA-N vomitoxin hydrate Natural products OCC12C(O)C(=O)C(C)=CC1OC1C(O)CC2(C)C11CO1 LINOMUASTDIRTM-UHFFFAOYSA-N 0.000 title abstract description 9
- 230000003278 mimic effect Effects 0.000 title abstract 5
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 230000003321 amplification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 150000004478 deoxynivalenol derivatives Chemical class 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000010353 genetic engineering Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000004088 simulation Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 abstract description 28
- 150000001413 amino acids Chemical class 0.000 abstract description 25
- 239000000126 substance Substances 0.000 abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 239000007790 solid phase Substances 0.000 abstract description 7
- 229920001184 polypeptide Polymers 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 230000002860 competitive effect Effects 0.000 abstract description 5
- 230000003302 anti-idiotype Effects 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract description 2
- 230000036046 immunoreaction Effects 0.000 abstract 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 241001416177 Vicugna pacos Species 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 206010014128 Echopraxia Diseases 0.000 description 2
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 2
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 2
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 2
- CQNFRKAKGDSJFR-NUMRIWBASA-N Thr-Glu-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O CQNFRKAKGDSJFR-NUMRIWBASA-N 0.000 description 2
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 2
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 2
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 2
- KRXFXDCNKLANCP-CXTHYWKRSA-N Tyr-Tyr-Ile Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 KRXFXDCNKLANCP-CXTHYWKRSA-N 0.000 description 2
- 108010064997 VPY tripeptide Proteins 0.000 description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 2
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 150000002304 glucoses Chemical class 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 108010009962 valyltyrosine Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QBUKAFSEUHGMMX-MTJSOVHGSA-N (5z)-5-[[3-(1-hydroxyethyl)thiophen-2-yl]methylidene]-10-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinolin-9-ol Chemical class C1=CC=2NC(C)(C)C=C(C)C=2C2=C1C=1C(OC)=C(O)C=CC=1O\C2=C/C=1SC=CC=1C(C)O QBUKAFSEUHGMMX-MTJSOVHGSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- XQJAFSDFQZPYCU-UWJYBYFXSA-N Ala-Asn-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N XQJAFSDFQZPYCU-UWJYBYFXSA-N 0.000 description 1
- JEPNLGMEZMCFEX-QSFUFRPTSA-N Ala-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)N JEPNLGMEZMCFEX-QSFUFRPTSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- SKTGPBFTMNLIHQ-KKUMJFAQSA-N Arg-Glu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SKTGPBFTMNLIHQ-KKUMJFAQSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
- CGYKCTPUGXFPMG-IHPCNDPISA-N Asn-Tyr-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O CGYKCTPUGXFPMG-IHPCNDPISA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 1
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 1
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 1
- KXTAGESXNQEZKB-DZKIICNBSA-N Glu-Phe-Val Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 KXTAGESXNQEZKB-DZKIICNBSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- HHRODZSXDXMUHS-LURJTMIESA-N Gly-Met-Gly Chemical compound CSCC[C@H](NC(=O)C[NH3+])C(=O)NCC([O-])=O HHRODZSXDXMUHS-LURJTMIESA-N 0.000 description 1
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 1
- 241000522978 Hafniaceae bacterium Species 0.000 description 1
- 241001640034 Heteropterys Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- PZWBBXHHUSIGKH-OSUNSFLBSA-N Ile-Thr-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PZWBBXHHUSIGKH-OSUNSFLBSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 1
- MHQXIBRPDKXDGZ-ZFWWWQNUSA-N Met-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)[C@@H](N)CCSC)C(O)=O)=CNC2=C1 MHQXIBRPDKXDGZ-ZFWWWQNUSA-N 0.000 description 1
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- DFEVBOYEUQJGER-JURCDPSOSA-N Phe-Ala-Ile Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O DFEVBOYEUQJGER-JURCDPSOSA-N 0.000 description 1
- XWBJLKDCHJVKAK-KKUMJFAQSA-N Phe-Arg-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N XWBJLKDCHJVKAK-KKUMJFAQSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- VEUACYMXJKXALX-IHRRRGAJSA-N Pro-Tyr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VEUACYMXJKXALX-IHRRRGAJSA-N 0.000 description 1
- 101710124584 Probable DNA-binding protein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- SLOYNOMYOAOUCX-BVSLBCMMSA-N Trp-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SLOYNOMYOAOUCX-BVSLBCMMSA-N 0.000 description 1
- ABRICLFKFRFDKS-IHPCNDPISA-N Trp-Ser-Tyr Chemical compound C([C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 ABRICLFKFRFDKS-IHPCNDPISA-N 0.000 description 1
- VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100001048 fetal toxicity Toxicity 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明属于生物技术领域,涉及基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原及其应用,氨基酸序列SEQ ID NO.:1,还涉及编码该氨基酸的核苷酸。本发明脱氧雪腐镰刀菌烯醇模拟抗原可以替代价格昂贵且毒性强的DON标准品,并作为竞争抗原或固相包被抗原应用于DON的免疫学检测,该模拟抗原具有与天然DON分子相似的免疫反应特性,效果良好。VHH相比于传统的基于多肽的抗原模拟表位及基于IgG的传统抗独特型抗体,具有结构更加稳定、耐酸碱和高温、检测灵敏度高等特性,因此其免疫检测稳定性得到了极大的提升,同时对环境的耐受能力也得到了提升。
Description
技术领域
本发明属于生物技术领域,具体涉及基于纳米抗体(单域重链抗体,Variabledomain of heavy chain of heavychain antibody, VHH)的脱氧雪腐镰刀菌烯醇模拟抗原及其应用。
背景技术
脱氧雪腐镰刀菌烯醇(deoxynivalneol,DON)是一种单端孢霉烯族毒素,主要由镰刀菌产生,广泛存在于大麦、小麦、玉米、燕麦和大米等农作物及其制品中。DON具有细胞毒性、胚胎毒性和免疫毒性等,可引起厌食、呕吐、腹泻、发烧和生长缓慢等症状,严重威胁人类及动物的健康。由于DON的高污染率和高毒性,对食品中DON的检测具有重要意义。
目前,检测食品中DON的方法主要有薄层色谱、高效液相色谱、气相色谱、表面等离子共振及免疫学检测等方法,免疫学检测方法由于其检测方便、成本低廉、灵敏度高等优势在DON的检测应用广泛。然而,在建立免疫学检测方法的过程中,必不可免的需要以DON标准品为原料来制备竞争抗原或者固相包被抗原,DON标准品不仅价格昂贵而且具有较强的毒性,对检测人员的健康和环境造成极大的威胁,从而在一定程度上制约了免疫学检测方法的应用和推广。因此,人们开始利用抗独特型抗体和抗原模拟表位来实现有害小分子物质标准品的替代,并取得了一定的进展。噬菌体展示技术的主要特点是可有效地筛选出与目标靶分子特异结合的噬菌体展示多肽,该技术在探索受体与配体之间相互作用结合位点、寻求高亲和力生物活性的配体分子、探索未知蛋白质空间结构表位、新型疫苗的研制等方面应用广泛。
本发明通过用噬菌体展示技术,从驼源天然单域重链抗体库中筛选能与靶分子(抗DON单克隆抗体)特异性结合的单域重链抗体(VHH),以VHH作为DON模拟抗原应用于免疫学分析检测领域。该方法避免了传统抗独特型抗体制备所需的动物免疫过程,且具有普遍适用性,筛选得到的VHH具有与天然DON分子相似的免疫反应特性,可替代价格昂贵且毒性强的DON标准品,并作为竞争抗原或固相包被抗原应用于DON的免疫学检测。VHH相比于传统的基于多肽的抗原模拟表位及基于IgG的的传统抗独特型抗体,具有结构更加稳定、耐酸碱和高温、检测灵敏度高等特性,因此其免疫检测稳定性得到了极大的提升,同时对环境的耐受能力也得到了提升。
发明内容
本发明以抗DON单克隆抗体为靶分子,将靶分子固相包被于酶标板上,投入驼源天然单域重链抗体库进行亲和淘选,获得了一种DON的模拟抗原,具有SEQ ID NO. :1所示的氨基酸序列。
其氨基酸序列的IMGT编号和结构域划分如图1所示。
本发明所提及的DON模拟抗原(VHH)包括四个框架区(Framework region, FR)和三个互补决定区(Complementarity-determining region, CDR)。其中,框架区(FR1-FR4)分别选自SEQ ID NO. :2,SEQ ID NO. :4,SEQ ID NO. :6和SEQ ID NO. :8,互补决定区(CDR1-CDR3)分别选自SEQ ID NO. :3,SEQ ID NO. :5和SEQ ID NO. :7。框架区结构相对保守,主要起着维持蛋白质结构的作用;互补决定区结构相对多样化,主要负责抗体的识别。
本发明提供一种蛋白质或多肽,包含SEQ ID NO. :2,SEQ ID NO. :4,SEQ ID NO.:6和SEQ ID NO. :8中的一个或两个及以上的氨基酸序列,且至少与其中一个的氨基酸序列有90%同源性。
本发明提供一种蛋白质或多肽,包含SEQ ID NO. :3,SEQ ID NO. :5和SEQ IDNO. :7中的一个或两个及以上的氨基酸序列,且至少与其中一个的氨基酸序列有80%同源性。
本发明还涉及编码脱氧雪腐镰刀菌烯醇模拟抗原氨基酸序列的核苷酸,其序列为SEQ ID NO. :9。
本发明提及的基于纳米抗体的DON模拟抗原(VHH)可通过噬菌体扩增或基因工程重组表达的方式进行大量制备。噬菌体扩增是指将展示有DON模拟抗原(VHH)的噬菌体,通过生物扩增的方式,大量繁殖生产展示有DON模拟抗原(VHH)的噬菌体粒子。基因工程重组表达的方式是指将编码模拟抗原的基因,通过克隆至表达载体,以蛋白表达的形式进行DON模拟抗原的大量制备。
本发明还涉及所述DON模拟抗原在免疫学检测分析中的应用。免疫学检测的类型包括酶联免疫吸附检测、胶体金免疫层析、免疫斑点杂交等基于抗原-抗体特异性反应的免疫学分析检测类型。
本发明DON模拟抗原在应用时,可以通过噬菌体扩增获得的展示有DON模拟抗原的噬菌体粒子直接用于分析检测,当然,也可以将DON模拟抗原经过原核生物或真核生物表达后以蛋白的形式进行免疫学检测分析。
本发明还涉及DON模拟抗原在免疫学检测分析中的应用,优选为DON模拟抗原在制备DON的模拟物试剂、材料中的应用。
本发明所述的氨基酸序列可以作为前体,通过随机或定点突变技术进行改造,能够获得性质(亲和力、特异性和稳定性等)更好的突变体。
本发明中所叙述的一些术语具有如下含义 :
同源性:描述两个或多个氨基酸序列的相似程度,第一个氨基酸序列和第二个氨基酸序列之间的同源性百分比可以通过【第一氨基酸序列中与第二氨基酸序列中相应位置处的氨基酸残基相同的氨基酸残基的数量】除以【第一个氨基酸序列中氨基酸总数】再乘以【100%】来计算,其中第二氨基酸序列中的某个氨基酸的缺失、 插入、 替换或添加 (与第一氨基酸相比)被认为是有差别。另外,同源性百分比也可以利用已知的用于序列比对的计算机运算程序(如:NCBI Blast) 获得。
结构域:蛋白质三级结构的基本结构单位,通常具有一定的功能。
IMGT 编号:IMGT 数据库 (The International ImMunoGeneTics Database)中的一种已经标准化的抗体氨基酸序列编号方法。具体编号方法可以参考文献 (Ehrenmann,F., Q. Kaas, et al.(2010). "IMGT/3Dstructure-DB and IMGT/DomainGapAlign: adatabase and a tool for immunoglobulins or antibodies, T cell receptors, MHC,IgSF and MhcSF." Nucleic Acids Res 38(Database issue): D301-307. Lefranc, M.P., C. Pommie, et al. (2003). "IMGT unique numbering for immunoglobulin and Tcell receptor variable domains and Ig superfamily V-like domains." Dev CompImmunol 27(1): 55-77.)中的描述。
密码子(codon):亦称三联体密码(triplet code),指对应于某种氨基酸的核苷酸三联体。在转译过程中决定该种氨基酸插入生长中多肽链的位置。
前述DON模拟抗原可以替换价格昂贵且毒性强的DON标准品,并作为竞争抗原或固相包被抗原应用于DON的免疫学检测,该模拟抗原具有与天然DON分子相似的免疫反应特性,效果良好。
本发明的有益效果是:本发明DON模拟抗原可以替代价格昂贵且毒性强的DON标准品,并作为竞争抗原或固相包被抗原应用于DON的免疫学检测。该模拟抗原具有与天然DON分子相似的免疫反应特性,可提高DON检测灵敏度,减少DON标准品对操作人员健康和环境的危害,节约成本。本发明DON模拟抗原具有耐酸碱耐热性能。本发明制备DON模拟抗原的方法具有普遍适用性,可用于其他小分子物质模拟抗原的筛选和制备,具有很高的应用价值。
附图说明
图1为DON模拟抗原(VHH)的氨基酸编号及结构域示意图。
图2为以DON模拟抗原建立的间接竞争ELISA标准曲线。检测范围为2.18-62.25ng/mL,IC50为8.77 ng/mL。
具体实施方式
实施例1.驼源天然单域重链抗体库的构建
1)驼源白细胞的分离:在离心管中加入淋巴细胞分离液,再加入血液样品,700g离心20min;小心吸取中间层悬浮的白细胞至一新的离心管中,加入1/2体积的PBS,800g离心15min;弃上清,用PBS洗下离心管壁上的白细胞,850g离心10min;弃上清,300μL PBS重悬白细胞并计数;以体积比1:10加入裂解液(RNAiso)保存备用。
2)总RNA提取:向上述裂解液中加入1/5体积的氯仿,剧烈震荡 15 s 使其充分乳化,室温静置 5 min;4℃ 12000g 离心 15 min,取上清转移至另一新鲜离心管中;加入等体积的异丙醇,充分混匀后室温静置10min;4℃ 12000g 离心 10 min,弃上清,缓慢加入75%乙醇1mL,小心洗涤离心管管壁;4℃,12000g 离心 5 min 后弃去乙醇;室温干燥沉淀 5min,加入适量的 RNase-free 水溶解沉淀,待 RNA 沉淀完全溶解后于 -80 ℃ 保存。
3)cDNA的合成:将反转录用的引物、dNTP Mixture和模板RNA混合,65 ℃ 5min,迅速冰浴。具体配制如下:
Oligo dT Primer(2.5 µM) | 1 µL |
dNTP Mixture(10 mM each) | 1 µL |
Total RNA | < 5 µg |
RNase free dH2O | 5 µL |
Total | 10 µL |
然后在上述 Microtube 中配置下列反转录反应液:
上述变性后反应液 | 10 µL |
5×PrimeScript Buffer | 4 µL |
RNase Inhibitor(40 U/µL) | 0.5 µL |
PrimeScript RTase(200 U/µL | 1 µL |
RNase free dH2O | 4.5 µL |
Total | 20 µL |
PCR 仪上按下列条件进行反转录反应:42 ℃ 30 min,50 ℃ 30 min,70 ℃ 10min。PCR 产物于 -20 ℃ 保存备用。
4)抗体可变区基因扩增:将反转录得到的cDNA作为模板进行PCR反应。
第一轮PCR:
5×PrimeSTAR Buffer | 10 µL |
dNTP Mixture(each 2.5 µM) | 4 µL |
Primer AlpVh-LD(10 µM) | 1 µL |
Primer CH2-R(10 µM) | 1 µL |
1 st-Strand cDNA | 1 µL |
PrimeSTAR HS DNA Polymerase(2.5 U/µL) | 0.5µL |
ddH2O | 32.5µL |
Total | 50 µL |
PCR 反应条件:94 ℃ 4 min;98 ℃ 10 s,55 ℃ 15 s,72 ℃ 45s,30 cycles;72℃ 7 min。
采用试剂盒回收 PCR 扩增产物,适当稀释后作为第二轮PCR的模板。
第二轮PCR:
5×PrimeSTAR Buffer | 10 µL |
dNTP Mixture(each 2.5 µM) | 4 µL |
Primer AlpVh-SfiⅠ | 1 µL |
Primer AlpVHHR1-NotⅠ/AlpVHHR2-NotⅠ | 1 µL |
第一轮PCR产物 | 1 µL |
PrimeSTAR HS DNA Polymerase(2.5 U/µL | 0.5µL |
ddH2O | 32.5µL |
Total | 50 µL |
PCR 反应条件:94 ℃ 4 min;98 ℃ 10 s,50 ℃ 15s,72 ℃ 45 s,5cycles;98℃ 10 s ,68 ℃ 40 s ,30cycles ; 72 ℃ 7 min。
5) 文库构建:
A. VHH编码基因及载体的双酶切
分别采用Sfi I和Not I 酶对VHH编码基因和pHEN1载体进行双酶切。
B. 酶切后产物的连接
将载体pHEN1和VHH片段混匀(摩尔比1∶5),于 16 ℃ 连接 12 h。先后加入 5 µL(1/10 量)的 3 M CH3COONa(pH 5.2)和 125 µL(2.5 倍量)的冷无水乙醇,-20 ℃ 静置1h,12000 rpm 离心回收沉淀,用 70 % 的冷乙醇清洗沉淀,室温干燥,溶于10 µL 去离子水中。
C. 电转化
取5 μL连接产物加至80 μL感受态细胞E.coli TG1中,充分混匀,冰上放置1min。转入0.1 cm 的电击杯中电击转化(电压为 1.8 kV),立即向电击杯中加入900µL SOC培养基,37 ℃ 180 rpm 培养1 h 。将菌液涂布于SOB-AG平板,37 ℃倒置培养过夜。
6)文库的救援:接种超过10倍库容量的细胞于100mL 2×YT/amp/2%葡萄糖,培养至OD600达0.5;加入辅助噬菌体(20:l感染复数),37℃,静置15min后,220rpm培养45min;4℃,3000g离心10min;弃上清,加入100mL新鲜的2×YT/amp/kan培养基重悬沉淀,30℃培养过夜;4℃ 3000g离心10min,取上清;加入1/5体积的PEG-NaCl溶液,4℃静置2h;4℃10000rpm离心20min,弃上清,沉淀用1mL PBS重悬;取10μL测定库容,其余加入终浓度50%甘油,-80℃保存。
实施例2.DON模拟抗原的亲和淘选及其鉴定
1)DON模拟抗原的亲和淘选:首先,用PBS (pH 7.4) 稀释抗DON单克隆抗体,并以终浓度10 μg/mL 包被酶标板,37 ℃孵育4 小时。第二天用PBST (10mM PBS,0.5 % Tween-20 (v/v) ) 洗涤3次后,加入300 μL的7 % BSA-PBS(3 % OVA-PBS)37℃封闭2小时。2小时后弃封闭液,用PBST洗涤5次,每孔加入100 μL驼源天然单域重链抗体库(滴度约2.0×1011cfu),37℃孵育1小时。吸出未结合的噬菌体,用PBST洗涤10次,加入100 μL的Glycine-HCl(0.2M, pH 2.2) 洗脱6-8min后,立即用15 μL Tris-HCl (1M,pH 9.1) 中和。取10 μL洗脱噬菌体测定滴度,其余的用于感染20 mL生长至对数期的E. coli TG1菌株进行扩增。第三天用PEG/NaCl沉淀扩增后的噬菌体,并测定噬菌体的滴度。
在第二、第三和第四轮的淘选过程中,包被的抗DON单克隆抗体浓度分别为7.5 μg/mL, 5 μg/mL和2.5 μg/mL,洗脱时采用竞争洗脱,所用DON标品浓度分别为5 μg/mL,1 μg/mL和0.5 μg/mL,加入噬菌体孵育后用PBST洗涤次数分别为10次,12次和15次,其余步骤同上。
2)阳性噬菌体克隆的鉴定: 从第三轮和第四轮淘选后测定噬菌体滴度的平板上随机挑取48个克隆,进行噬菌体的扩增,采用间接酶联免疫吸附检测方法(IndirectEnzyme Linked immunoasorbent assay, I-ELISA)进行阳性噬菌体克隆的鉴定。具体方法为:首先,用PBS (pH 7.4) 将抗DON单克隆抗体稀释至 10 µg/mL,4℃包被过夜。第二天用PBST (10 mM PBS, 0.05% Tween-20 (v/v) )洗涤3次后,加入300µL的5%脱脂奶粉,37℃封闭2小时;弃封闭液,PBST洗涤3次后,加入100 µL噬菌体扩增液(2.0×1011 cfu),以原始噬菌体肽库作为阴性对照,37℃孵育1小时;加入1:5000倍稀释的HRP标记抗M13噬菌体二抗100 µL,37 ℃孵育1小时;加入100µL TMB底物溶液,避光显色10min;加入50µL终止液(2MH2SO4)终止反应;用酶标仪(Thermo Scientific Multiskan FC)测定450 nm处的吸收值。选取OD450大于阴性对照2倍的噬菌体克隆为阳性克隆。
3) DON模拟抗原的鉴定:采用间接竞争ELISA的方法进行DON模拟抗原的鉴定,具体方法为:用PBS (pH 7.4) 将抗DON单克隆抗体稀释至10 µg/mL, 4℃包被过夜;第二天用PBST (10 mM PBS, 0.05% Tween-20 (v/v)) 洗涤3次后,加入300µL的5%脱脂奶粉,37℃孵育1小时;加入50 µL经间接ELISA鉴定为阳性的噬菌体克隆(1.0×1011 cfu)和50 µL DON标准品(浓度范围为0-100 ng/ml),37℃孵育1小时;加入1:5000稀释HRP标记的抗M13噬菌体二抗100 µL,37℃孵育1小时;加入100µL TMB底物溶液,避光显色10min,测定OD450,能结合抗DON单克隆抗体,且能被DON标准品所阻断的噬菌体,鉴定为DON的模拟抗原。
实施例3.DON模拟抗原编码基因的测序及其氨基酸序列的确定
将经过间接竞争ELISA鉴定展示有DON模拟抗原的噬菌体克隆进行DNA测序,根据DNA测序结果及密码子表可获得DON模拟抗原的氨基酸序列。得本发明模拟抗原氨基酸,序列如SEQ ID NO. :1。
实施例4.DON模拟抗原的大量制备
(1)以噬菌体扩增的方式进行制备
将展示有模拟抗原的噬菌体加入至20 mL接种有E.coli TG1的培养物中,37℃220 rpm振荡培养6 h。将培养物转入另一离心管中,4 ℃ 10000 rpm离心10 min,将上清的上部80 %转入一新鲜的离心管中,加入1/6体积的PEG/NaCl,4 ℃静置120 min后,4℃10000 rpm离心10min,弃上清;再加入少量PBS清洗噬菌体。4℃ 10000 rpm离心10min,弃上清,加入1mL PBS进行重悬,即为噬菌体扩增液。
(2)以蛋白表达的形式进行制备
分别采用Nco I和Not I 酶对外源编码VHH基因和表达载体(pET-25b)进行双酶切,将VHH编码基因克隆至表达载体pET-25b,经PCR和酶切验证后,将重组表达载体转入大肠杆菌Rosetta(DE3)。从转化平板上挑一单菌落接种于5 mL LB液体培养基中,37℃,220r/min振荡培养过夜,将过夜培养物按1 %接种量(v/v)接种于50 mL的LB/Amp,2 %葡萄糖培养基中,37℃,220 r/min振荡培养;当培养物菌体浓度OD600达到0.5时,向培养物中加入0.1mM的IPTG,30℃,220 r/min振荡培养8-12h;将培养物于4℃,8000rpm,离心20 min收集菌体沉淀。重悬细胞于5mL 预冷的PBS溶液,超声破碎10min后,8000rpm离心20min取上清,将上清进行亲和层析纯化,即得DON模拟抗原(VHH)。
实施例5.DON模拟抗原耐酸碱实验
(1)包被及封闭
用10 mM PBS (pH 7.4) 将抗DON单克隆抗体稀释至10 µg/mL,100µL包被于酶标板,4℃孵育过夜。第二天用PBST (10 mM PBS, 0.05% Tween-20 (v/v)) 洗涤3次后,用含有5%脱脂奶粉的PBS进行封闭,37℃孵育1小时后,用PBST洗板6次待用。
(2)活性检测
将本发明DON模拟抗原(VHH)分别用pH 5.0,6.0,7.0,8.0和9.0的PBS稀释至10 µg/mL,取100µL加入步骤(1)处理好的板条中,37℃孵育1小时。加入1:3000稀释HRP标记的抗His二抗,37℃孵育1小时。然后用TMB底物显色,读取OD450。比较不同pH条件下的吸光度值,结果显示VHH置于在pH 5.0-9.0的溶液中,其免疫检测性能(OD值)未见区别,显示出较好的耐酸碱性能。
实施例6.DON模拟抗原耐热实验
(1)包被及封闭
用10 mM PBS (pH 7.4) 将抗DON单克隆抗体稀释至10 µg/mL,100µL包被于酶标板,4℃孵育过夜。第二天用PBST (10 mM PBS, 0.05% Tween-20 (v/v)) 洗涤3次后,用含有5%脱脂奶粉的PBS进行封闭,37℃孵育1小时后,用PBST洗板6次待用。
(2)活性检测
用10 mM PBS (pH 7.4) 将DON模拟抗原(VHH)稀释至10 µg/mL,分别置于50,60,70,80和90℃水浴5min,恢复到室温后,再分别取100µL加入步骤(1)处理好的板条中,37℃孵育1小时。加入1:3000稀释HRP标记的抗His二抗,37℃孵育1小时。然后用TMB底物显色,读取OD450。比较不同温度处理条件下的吸光度值,结果显示VHH置于在50-90℃水浴5min后,其免疫检测性能(OD值)未见区别,显示出较好的耐热性能。
实施例7.DON模拟抗原作为竞争抗原在ELISA中的应用
(1) 样品提取
称取1g 样品(谷物及其相关制品),加入5 毫升PBS(pH 7.4)溶液,充分振荡5分钟;将提取液用whatman 1号滤纸进行过滤,取1毫升滤液加入1毫升 PBS混匀后,即为样品提取液,待用。
(2)包被及封闭
用10 mM PBS (pH 7.4)将抗DON单克隆抗体稀释至10 µg/mL, 4℃包被过夜。第二天用PBST (10 mM PBS, 0.05% Tween-20 (v/v)) 洗涤3次,加入300µL的5%脱脂奶粉, 37℃封闭1小时后,用PBST洗板6次待用。
(3)标准曲线的建立
取出经步骤(2)处理好的板条,每孔分别投入50 µL展示有DON模拟抗原的噬菌体(1.0×1011 cfu)/VHH蛋白表达物(10µg/mL)及一系列不同浓度的50 µL DON标准品,37℃孵育1小时。加入1:5000稀释HRP标记的抗M13噬菌体二抗/抗VHH的组氨酸标签二抗,37℃孵育1小时。然后用TMB底物显色,读取OD450。以DON浓度对数为横坐标,结合率(加入DON的孔的OD450/未加入DON的孔的OD450×100%)为纵坐标,建立间接竞争标准曲线。
(4)样品的检测
取出经步骤(2)处理好的板条,每孔分别投入50 µL展示有DON模拟抗原的噬菌体(1.0×1011 cfu)/VHH蛋白表达物(10µg/mL)及待测样品提取液,37℃孵育1小时。加入1:5000稀释HRP标记的抗M13噬菌体二抗/抗VHH的组氨酸标签二抗,37℃孵育1小时。然后用TMB底物显色,读取OD450,计算结合率,并根据标准曲线,倒推出样品中DON的含量。
实施例8.DON模拟抗原作为固相包被抗原在ELISA中的应用
(1) 样品提取
称取1g 样品(谷物及其相关制品),加入5 毫升PBS(pH 7.4)溶液,充分振荡5分钟;将提取液用whatman 1号滤纸进行过滤,取1毫升滤液加入1毫升 PBS混匀后,即为样品提取液,待用。
(2)包被及封闭
用10 mM PBS (pH 7.4) 将表达的DON模拟抗原(VHH)稀释至10µg/mL,100µL包被于酶标板,4℃孵育过夜。第二天用PBST (10 mM PBS, 0.05% Tween-20 (v/v)) 洗涤3次后,用含有5%脱脂奶粉的PBS进行封闭,37℃孵育1小时后,用PBST洗板6次待用。
(3)标准曲线的建立
取出经步骤(2)处理好的板条,每孔分别投入50 µL 抗DON单克隆抗体(5µg/ml)和一系列不同浓度的50 µL DON标准品,37℃孵育1小时。加入1:2000稀释HRP标记的羊抗鼠IgG二抗,37℃孵育1小时。然后用TMB底物显色,读取OD450。以DON标准品浓度对数为横坐标,结合率(加入DON的孔的OD450/未加入DON的孔的OD450×100%)为纵坐标,建立间接竞争标准曲线。结果显示标准曲线呈S型,线性相关性较好,检测范围为2.18-62.25 ng/mL,IC50为8.77 ng/mL(图1)。
(4)样品的检测
取出经步骤(2)处理好的板条,每孔分别投入50 µL 抗DON单克隆抗体(5µg/ml)和待测样品提取液,37℃孵育1小时。加入1:2000稀释HRP标记的羊抗鼠IgG二抗,37℃孵育1小时。然后用TMB底物显色,读取OD450。计算结合率,并根据标准曲线,倒推出样品中DON的含量。
SEQUENCE LISTING
<110> 南昌大学
<120> 基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原及其应用
<130> 2014
<160> 9
<170> PatentIn version 3.3
<210> 1
<211> 122
<212> PRT
<213> Lama pacos
<400> 1
Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr
20 25 30
Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Glu Glu Arg Glu Phe Val
35 40 45
Ala His Ile Thr Arg Leu Gly Val Thr Tyr Tyr Ile Asp Ser Val Lys
50 55 60
Gly Arg Phe Ala Ile Ser Arg Asp Asn Thr Glu Asn Thr Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Ala Arg Arg Gly Ser Thr Val Pro Tyr Ser Ala Asn Tyr Trp Ser Tyr
100 105 110
Trp Gly Gln Gly Thr Gln Val Thr Val Ser
115 120
<210> 2
<211> 25
<212> PRT
<213> Lama pacos
<220>
<221> Domain
<222> (1)..(25)
<223> FR1
<400> 2
Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25
<210> 3
<211> 8
<212> PRT
<213> Lama pacos
<220>
<221> Domain
<222> (1)..(8)
<223> CDR1
<400> 3
Gly Arg Thr Phe Ser Ser Tyr Gly
1 5
<210> 4
<211> 17
<212> PRT
<213> Lama pacos
<220>
<221> Domain
<222> (1)..(17)
<223> FR2
<400> 4
Met Gly Trp Phe Arg Gln Ala Pro Gly Glu Glu Arg Glu Phe Val Ala
1 5 10 15
His
<210> 5
<211> 7
<212> PRT
<213> Lama pacos
<220>
<221> Domain
<222> (1)..(7)
<223> CDR2
<400> 5
Ile Thr Arg Leu Gly Val Thr
1 5
<210> 6
<211> 38
<212> PRT
<213> Lama pacos
<220>
<221> Domain
<222> (1)..(38)
<223> FR3
<400> 6
Tyr Tyr Ile Asp Ser Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn
1 5 10 15
Thr Glu Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp
20 25 30
Thr Ala Val Tyr Tyr Cys
35
<210> 7
<211> 17
<212> PRT
<213> Lama pacos
<220>
<221> Domain
<222> (1)..(17)
<223> CDR3
<400> 7
Ala Ala Arg Arg Gly Ser Thr Val Pro Tyr Ser Ala Asn Tyr Trp Ser
1 5 10 15
Tyr
<210> 8
<211> 11
<212> PRT
<213> Lama pacos
<220>
<221> Domain
<222> (1)..(11)
<223> FR4
<400> 8
Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
1 5 10
<210> 9
<211> 366
<212> DNA
<213> Lama pacos
<400> 9
ggagacggtg acctgggtcc cctggcccca gtaggaccag taattagcac tataaggtac 60
tgtcgaaccc cgtctagctg cacagtaata aacggccgtg tcctcaggtt tcaggctgtt 120
catttgcaga tacaccgtgt tctcggtgtt gtctctggag atggcgaatc ggcccttcac 180
ggagtctata tagtatgtaa caccaagccg tgtaatatgc gctacgaatt cacgctcctc 240
ccctggagcc tggcggaacc agcccatgcc ataactactg aaggtgcgtc cagaggctgc 300
acaggagagt ctcagagagc ccccagcctg caccaatcct cccccagact ccacgagctg 360
caactg 366
Claims (3)
1.基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原,其氨基酸序列如SEQ ID NO. :1所示。
2.编码权利要求1所述脱氧雪腐镰刀菌烯醇模拟抗原氨基酸序列的核苷酸,其序列为SEQ ID NO. :9。
3.如权利要求1所述模拟抗原的制备方法,其特征在于通过噬菌体扩增或基因工程重组表达的方式进行大量制备;所述噬菌体扩增是指将展示有脱氧雪腐镰刀菌烯醇模拟抗原的噬菌体,通过生物扩增的方式,大量繁殖生产展示有脱氧雪腐镰刀菌烯醇模拟抗原的噬菌体粒子;所述基因工程重组表达的方式是指将编码模拟抗原的基因,通过克隆至表达载体,以蛋白表达的形式进行脱氧雪腐镰刀菌烯醇模拟抗原的大量制备。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410535171.4A CN104311643B (zh) | 2014-10-13 | 2014-10-13 | 基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410535171.4A CN104311643B (zh) | 2014-10-13 | 2014-10-13 | 基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104311643A CN104311643A (zh) | 2015-01-28 |
CN104311643B true CN104311643B (zh) | 2017-04-12 |
Family
ID=52366979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410535171.4A Expired - Fee Related CN104311643B (zh) | 2014-10-13 | 2014-10-13 | 基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104311643B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108101970A (zh) * | 2017-12-14 | 2018-06-01 | 江苏省农业科学院 | 基于抗独特型纳米抗体的Cry1Ab毒素模拟抗原及其应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105218675B (zh) * | 2015-08-31 | 2018-08-17 | 南昌大学 | 可特异性结合抗玉米赤霉烯酮抗体的纳米抗体及其应用 |
CN105218676B (zh) * | 2015-08-31 | 2018-08-24 | 南昌大学 | 玉米赤霉烯酮抗独特型纳米抗体及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101983970A (zh) * | 2010-01-28 | 2011-03-09 | 江苏省农业科学院 | 抗呕吐毒素DON单链抗体ScFv及其制备方法与应用 |
-
2014
- 2014-10-13 CN CN201410535171.4A patent/CN104311643B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101983970A (zh) * | 2010-01-28 | 2011-03-09 | 江苏省农业科学院 | 抗呕吐毒素DON单链抗体ScFv及其制备方法与应用 |
Non-Patent Citations (4)
Title |
---|
Isolation and characterisation of deoxynivalenol affinity binders from a phage display library based on single-domain camelid heavy chain antibodies(VHHs);Zhui Tu et al;《Food and Agricultural Immunology》;20120818;第23卷(第2期);123-131 * |
基于单域重链抗体的天然噬菌体文库的构建及抗DON适配体的淘选;涂追;《南昌大学博士学位论文》;20110803;1-74 * |
抗脱氧雪腐镰刀菌烯醇噬菌体单链抗体库的构建与鉴定;周艳红 等;《江苏农业学报》;20101231;第26卷(第5期);1093-1097 * |
脱氧雪腐镰刀菌烯醇噬菌体单链抗体库的构建及原核表达;黄星星;《南京农业大学硕士学位论文》;20140815;2-65 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108101970A (zh) * | 2017-12-14 | 2018-06-01 | 江苏省农业科学院 | 基于抗独特型纳米抗体的Cry1Ab毒素模拟抗原及其应用 |
CN108101970B (zh) * | 2017-12-14 | 2021-02-26 | 江苏省农业科学院 | 基于抗独特型纳米抗体的Cry1Ab毒素模拟抗原及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104311643A (zh) | 2015-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104592389B (zh) | 抗脱氧雪腐镰刀菌烯醇抗体的纳米抗体 | |
KR101491835B1 (ko) | 하이브리도머 세포주 10g4 및 그가 생성하는 항아플라톡신 b1, b2, g1, g2 총량 모노클론 항체 | |
CN105037544B (zh) | 基于afp抗原的afp纳米抗体a83 | |
CN105218676B (zh) | 玉米赤霉烯酮抗独特型纳米抗体及其应用 | |
CN105037547B (zh) | 基于afp抗原的afp纳米抗体a18 | |
CN103866401A (zh) | 一种黄曲霉毒素纳米抗体基因库、构建方法、用途及黄曲霉毒素b1纳米抗体2014afb-g15 | |
CN105037546B (zh) | 基于afp抗原的afp纳米抗体a65 | |
CN104311643B (zh) | 基于纳米抗体的脱氧雪腐镰刀菌烯醇模拟抗原及其应用 | |
CN110526967A (zh) | 一种金黄色葡萄球菌肠毒素a纳米抗体a13、应用及试剂盒 | |
CN109535251A (zh) | 一种赭曲霉毒素a抗独特型纳米抗体及其制备方法 | |
CN107602701A (zh) | 基于抗独特型纳米抗体的玉米赤霉烯酮绿色免疫分析方法 | |
CN105037545B (zh) | 基于afp抗原的afp纳米抗体a80 | |
CN105218675B (zh) | 可特异性结合抗玉米赤霉烯酮抗体的纳米抗体及其应用 | |
CN103361741B (zh) | 一种噬菌体抗体库及其在盐酸克伦特罗含量测定中的应用 | |
CN103965358B (zh) | 模拟桔青霉素抗原的纳米抗体及其应用 | |
CN115925913B (zh) | 特异性识别金黄色葡萄球菌肠毒素b、c的纳米抗体bc16及其应用 | |
CN110317241A (zh) | 抗Cry1Da蛋白的多肽分子及其应用 | |
CN106084060B (zh) | 抗呕吐毒素抗原-抗体免疫复合物的纳米抗体及其应用 | |
CN103848895B (zh) | 黄曲霉毒素b1的线性十二肽抗原模拟表位及其应用 | |
CN106478777B (zh) | 具有免疫保护性的金黄色葡萄球菌FnBPA‑A蛋白模拟表位肽、模拟表位肽组合物及其应用 | |
CN102492037B (zh) | 一种高亲和力镰刀菌特异单链抗体及制备方法 | |
CN105315346B (zh) | 可特异性结合脱氧雪腐镰刀菌烯醇的多肽分子及其应用 | |
CN104804070B (zh) | 可特异性结合玉米赤霉烯酮的多肽分子及其应用 | |
CN109575138B (zh) | 一种赭曲霉毒素a抗独特型纳米抗体作为赭曲霉毒素a抗原替代物的应用 | |
CN103159853A (zh) | 全人源抗丙型肝炎病毒核心抗原的基因工程Fab抗体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170412 |